These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23157681)

  • 21. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
    Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A combination chemotherapy with adriamycin, cyclophosphamide and DTIC (ACD) for advanced adult soft part sarcoma].
    Ikeda K; Ogawa M; Inagaki J; Horikoshi N; Inoue K; Usui N; Nakada H; Adachi K; Okada Y
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):235-9. PubMed ID: 6696459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
    Pápai Z; Bodoky G; Szántó J; Poller I; Rahóty P; Eckhardt S; Láng I; Szendroi M
    Cancer; 2000 Jul; 89(1):177-80. PubMed ID: 10897015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
    Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
    Okuno S; Maples WJ; Mahoney MR; Fitch T; Stewart J; Fracasso PM; Kraut M; Ettinger DS; Dawkins F; Erlichman C
    J Clin Oncol; 2005 May; 23(13):3069-73. PubMed ID: 15860865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib in patients with refractory or recurrent multiple myeloma.
    Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
    Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
    Patel SR; Beach J; Papadopoulos N; Burgess MA; Trent J; Jenkins J; Benjamin RS
    Cancer; 2003 Jun; 97(11):2848-52. PubMed ID: 12767099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
    Guidetti A; Carlo-Stella C; Locatelli SL; Malorni W; Mortarini R; Viviani S; Russo D; Marchianò A; Sorasio R; Dodero A; Farina L; Giordano L; Di Nicola M; Anichini A; Corradini P; Gianni AM
    Clin Cancer Res; 2014 Nov; 20(22):5641-51. PubMed ID: 25239609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib after RFA in HCC patients: a pilot study.
    de Stefano G; Farella N; Scognamiglio U; Liorre G; Calabria G; Ascione T; Giorgio A; Iodice V
    Hepatogastroenterology; 2015; 62(138):261-3. PubMed ID: 25916044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
    Srkalovic G; Hussein MA; Hoering A; Zonder JA; Popplewell LL; Trivedi H; Mazzoni S; Sexton R; Orlowski RZ; Barlogie B
    Cancer Med; 2014 Oct; 3(5):1275-83. PubMed ID: 24913924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
    Sullivan RJ; Ibrahim N; Lawrence DP; Aldridge J; Giobbie-Hurder A; Hodi FS; Flaherty KT; Conley C; Mier JW; Atkins MB; McDermott DF
    Oncologist; 2015 Jun; 20(6):617-8. PubMed ID: 25986244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience.
    Deutschbein T; Matuszczyk A; Moeller LC; Unger N; Yuece A; Lahner H; Mann K; Petersenn S
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):540-3. PubMed ID: 21667440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.
    Santoro A; Comandone A; Basso U; Soto Parra H; De Sanctis R; Stroppa E; Marcon I; Giordano L; Lutman FR; Boglione A; Bertuzzi A
    Ann Oncol; 2013 Apr; 24(4):1093-8. PubMed ID: 23230134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
    Meyer A; Cygan P; Tolzien K; Galvez AG; Bitran JD; Lestingi TM; Nabhan C
    Clin Genitourin Cancer; 2014 Apr; 12(2):100-5. PubMed ID: 24169494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
    Eigentler TK; Weide B; de Braud F; Spitaleri G; Romanini A; Pflugfelder A; González-Iglesias R; Tasciotti A; Giovannoni L; Schwager K; Lovato V; Kaspar M; Trachsel E; Menssen HD; Neri D; Garbe C
    Clin Cancer Res; 2011 Dec; 17(24):7732-42. PubMed ID: 22028492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
    Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
    Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
    Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
    Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.